Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Testosterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 4/20 | 0.75 |
| ▸ | LMNA | P02545 | 8/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.75 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.75 |
| ▸ | TSHR | P16473 | 5/20 | 0.75 |
| ▸ | MAPT | P10636 | 5/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.75 |
| ▸ | SHBG | P04278 | 4/20 | 0.75 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.75 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.75 |
| ▸ | PGR | P06401 | 4/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.75 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.75 |
| ▸ | SNCA | P37840 | 2/20 | 0.75 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.75 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.75 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Testosterone SCHEMBL2023832 | 1.00 | LMNA (0.75) | LMNACYP3A4CYP19A1TSHRMAPT | |
| Testosterone SCHEMBL5080100 | 1.00 | LMNA (0.75) | LMNACYP3A4CYP19A1TSHRMAPT | |
| Behenic Acid SCHEMBL11429128 | 1.00 | LMNA (0.75) | LMNACYP3A4CYP19A1TSHRMAPT | |
| Testosterone SCHEMBL5082498 | 1.00 | LMNA (0.75) | LMNACYP3A4CYP19A1TSHRMAPT | |
| Testosterone SCHEMBL1087216 | 1.00 | LMNA (0.75) | LMNACYP3A4CYP19A1TSHRMAPT | |
| Testosterone SCHEMBL42688 | 1.00 | LMNA (0.75) | LMNACYP3A4CYP19A1TSHRMAPT | |
| Testosterone SCHEMBL5078860 | 1.00 | LMNA (0.75) | LMNACYP3A4CYP19A1TSHRMAPT | |
| Testosterone SCHEMBL14694449 | 0.99 | LMNA (0.77) | LMNACYP3A4CYP19A1TSHRMAPT | |
| Testosterone SCHEMBL14694321 | 0.96 | LMNA (0.78) | LMNACYP3A4CYP19A1TSHRMAPT | |
| Testosterone SCHEMBL8075829 | 0.95 | LMNA (0.83) | LMNACYP3A4CYP19A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115128178-B | Full-automatic detection method for various steroid esters in dried blood spot sample | 上海体育大学 | 2023-08-25 | — | — | CN | claimed |
| US-9452174-B2 | Oral transmucosal pharmaceutical compositions including testosterone and a C-SERM | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA (US) | 2016-09-27 | — | — | US | claimed |
| US-20160051564-A1 | Oral Transmucosal Pharmaceutical Compositions Including Testosterone and a C-SERM | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA (PCCA) | 2016-02-25 | — | — | US | claimed |
| WO-2016028903-A1 | ORAL TRANSMUCOSAL PHARMACEUTICAL COMPOSITIONS INCLUDING TESTOSTERONE AND A C-SPERM | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA (US) | 2016-02-25 | — | — | WO | claimed |
| US-20130022674-A1 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME | CLARUS THERAPEUTICS, INC. (US) | 2013-01-24 | — | — | US | claimed |
| US-20080317844-A1 | Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Compositions Comprising Same | CLARUS THERAPEUTICS, INC. (US) | 2008-12-25 | — | — | US | claimed |
| CN-101217963-A | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same | CLARUS THERAPEUTICS INC (US) | 2008-07-09 | — | — | CN | claimed |
| EP-1871384-A2 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME | Clarus Therapeutics, Inc. (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2006113505-A2 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME | CLARUS THERAPEUTICS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
| EP-1418920-A4 | AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS INC (US) | 2006-10-04 | — | — | EP | claimed |
| EP-1418920-A1 | AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003011300-A1 | AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-20030022875-A1 | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness | VIVUS INC. | 2003-01-30 | — | — | US | claimed |
| US-12558361-B1 | Method and composition for treating non-cirrhotic NASH | LIPOCINE, INC. | 2026-02-24 | — | — | US | disclosed |
| CN-121568697-A | Testosterone dodecanoate compositions and methods | 来普卡公司 | 2026-02-24 | — | — | CN | disclosed |
| US-12527803-B2 | Testosterone dodecanoate compositions and methods | LIPOCINE, INC. | 2026-01-20 | — | — | US | disclosed |
| EP-2979699-A1 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME | Clarus Therapeutics, Inc. (US) | 2016-02-03 | — | — | EP | disclosed |
| US-4220599-A | HORMONES | AKZONA INCORPORATED (US) | 1980-09-02 | — | — | US | disclosed |
| US-4147783-A | ANDROGENS, ESTERS OF TESTOSTERONE AND DERIVATIVES | AKZONA INCORPORATED (US) | 1979-04-03 | — | — | US | disclosed |
| US-4098802-A | STEROIDS | AKZONA INCORPORATED (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022875-A1 | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness | SHBG, FSHR, GNRHR | AR 12/4885LMNA 4836/4885CYP3A4 316/4885 |
| US-12527803-B2 | Testosterone dodecanoate compositions and methods | SHBG, TNNT2, TNNI3 | AR 16/4885LMNA 269/4885CYP3A4 796/4885 |
| US-12558361-B1 | Method and composition for treating non-cirrhotic NASH | LIPC, SHBG, MTTP | AR 53/4885LMNA 754/4885CYP3A4 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.